secwatch.observer — SEC 8-K summary
======================================

Issuer:     Progyny, Inc. (PGNY)
CIK:        0001551306
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001551306-23-000060
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Progyny Q2 revenue $279.4M (+43% YoY); raises full-year guidance
----------------------------------------------------------------

- Revenue $279.4M (+43% YoY); net income $15.0M ($0.15 diluted EPS) vs $8.8M ($0.09) YoY.
- Adjusted EBITDA $47.5M (+44% YoY); record operating cash flow $76.0M, helped by new pharmacy partner agreements.
- Clients grew to 384 (from 273); ART cycles 14,771 (+42% YoY); utilization rates improved.
- FY 2023 revenue guidance raised to $1,075-1,090M (37-39% growth); adj EBITDA guided $183-187.5M.
- Q3 2023 revenue guided $268-273M; adj EBITDA $44.7-46.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551306/000155130623000060/0001551306-23-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551306/000155130623000060/pgny-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001551306-23-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer